Selected Grants
ASCENT-05 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2024 - 2029A Phase II Study of NirAparib, Dostarlimab and Radiotherapy in Metastatic, PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR) TBCRC-055 20-649
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2024 - 2028A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2022 - 2027Preventing Inflammatory Breast Cancer Metastases by Interrupting Cellular Stress Signaling in Lymphatic Emboli and Circulating Tumor Cell Clusters
ResearchCo Investigator · Awarded by Department of Defense · 2020 - 2025A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2023 - 2024Translational Breast Cancer Research Consortium 2023 Infrastructure (BCRF)
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2023 - 2024Translational Breast Cancer Research Consortium 2023 Infrastructure - SGK
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2023 - 2024Translational Breast Cancer Research Consortium 2022 Infrastructure - SGK
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2022 - 2024Translational Breast Cancer Research Consortium 2022 Infrastructure (BCRF)
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2022 - 2024Cardiovascular Impact of Near-complete Estrogen Deprivation for Breast Cancer
ResearchPrincipal Investigator · Awarded by Wake Forest University School Of Medicine · 2022 - 2023Translational Breast Cancer Research Consortium 2021 Infrastructure - SGK
Clinical TrialPrincipal Investigator · Awarded by Susan G. Komen Breast Cancer Foundation · 2021 - 2023Translational Breast Cancer Research Consortium 2021 Infrastructure (BCRF)
Clinical TrialPrincipal Investigator · Awarded by Susan G. Komen Breast Cancer Foundation · 2021 - 2023CardiovAscular Risk profile and Treatment patterns in ER+HER2 - Advanced Breast Cancer: A retrospective cohort study (CAREB)
ResearchPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2019 - 2022A PHASEIB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER
Clinical TrialPrincipal Investigator · Awarded by F. Hoffmann-La Roche Ltd · 2019 - 2022External Relationships
- AstraZeneca
- Bristol-Myers Squibb (BMS)
- Myocardial Solutions
- Novartis pharmaceuticals
- Pfizer Inc.
- RACE Oncology
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.